Stelis Biopharma appoints Mark Womack as new CEO

pharmafile | August 25, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Stelis Biopharma Limited has announced the appointment of Mark W Womack as the new Chief Executive Officer.

Womack is also the Managing Director designate and shall be inducted to the Board later, subject to necessary statutory clearances and processes.

Arun Kumar, Founder, Strides Group, said, “We are delighted to onboard Mark as the new CEO of Stelis. Mark’s strong background in commercial leadership, rich management consulting experience, and network within the biotech CDMO space make him exceptionally well suited to drive this transition for Stelis.”

Related Content

No items found

Latest content